You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
李氏大藥廠(00950.HK):下泌尿道感染治療藥物普盧利沙星片獲頒發進口藥品註冊證
格隆匯 06-26 08:14

格隆匯 6 月 26日丨李氏大藥廠(00950.HK)發佈公告,2020年6月12日,公司全資附屬公司李氏大藥廠(香港)有限公司的Unidrox®(普盧利沙星片)成功獲中國國家藥品監督管理局頒發進口藥品註冊證,該藥物用於治療急性無併發症下泌尿道感染(單純性膀胱炎)、併發症下泌尿道感染、慢性支氣管炎急性加重或急性細菌性鼻竇炎患者。普盧利沙星由意大利公司Angelini Pharma製造。

根據《民族藥理學雜誌(Journalof Ethnopharmacology)》(2019年第241期),泌尿道感染的發病率佔中國總人口0.91%。中國40歲以上人羣中慢性支氣管炎的患病率高達8.2%。根據2015年社區獲得性感染資料,慢性支氣管炎反覆急性加重會降低患者的生命質素、加劇肺功能障礙及提高死亡率。

兒童比成人更易患上急性細菌性鼻竇炎。根據香港衞生署的資料,估計兒童患上細菌性鼻竇炎而引致併發症病毒性感冒的發病率為6%至9%,而成人則為0.5%至2%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account